Open Government Portal
Found 10 records similar to Canadians crossing the border daily to attend school in the United States: How to quarantine at home during COVID-19
The World Health Organization (WHO) refers to symptoms lasting for weeks or months after a COVID-19 infection as post COVID-19 condition. Some studies have reported later symptoms in patients with a severe COVID-19 infection. For example, those who were hospitalized or needed intensive care during recovery. However, post COVID-19 condition may also occur for people with mild or asymptomatic infection who were asked to isolate at home during the infectious phase.
When people still show symptoms of COVID-19 for weeks or months after their initial recovery, it’s called post COVID-19 condition. It’s also known as long COVID. Post COVID-19 condition may occur in some people after infection.
The purpose of this document is to assist in planning immunization clinics for COVID-19 vaccines during the COVID-19 pandemic.
Pregnancy increases the risk of severe illness from COVID-19. The National Advisory Committee on Immunization (NACI) recommends you get a complete series with an mRNA COVID-19 vaccine if you're pregnant or breastfeeding. Getting the COVID-19 vaccine can prevent serious illness, hospitalization and complications.
Variant strains of SARS-CoV-2 are emerging that may affect the level of protection provided by currently authorized COVID-19 vaccines. As a result, manufacturers are adapting authorized COVID-19 vaccines to provide protection against infection and disease caused by virus variants.
COVID-19 is a new disease not previously identified in humans. Currently there is no vaccine or therapeutic product for COVID-19 that is authorized to treat or prevent the disease. The outbreak of COVID-19 has resulted in a global review of therapies that could be used to treat or prevent the infection. In an effort to facilitate earlier access to a vaccine, or therapeutic product for COVID-19, the Department will expedite the review of any COVID-19 related health product submissions and applications.
The file comprises COVID-19 case counts, population, demographic and air pollution data by health region. The data were employed in a national ecological study of the association between air pollution and incidence of COVID-19. Data were obtained from the COVID-19 Canada Open Data portal, the Canadian Urban Environmental Health Research Consortium (CANUE), Statistics Canada and Google COVID-19 Community Mobility Reports. The study found that there was a positive association between COVID-19 incidence and long-term exposure to fine particulate matter (PM2.5).
The medicine regulators from Australia, Canada, Singapore, Switzerland and the United Kingdom (Access Consortium) have discussed the regulatory evidence requirements for COVID-19 vaccine approvals and considerations for post-market pharmacovigilance. This collective statement on COVID-19 vaccines builds on the Consortium's May 2020 pledge to work together to counter the COVID-19 global pandemic.
What being vaccinated against COVID-19 means for me. By getting vaccinated, you benefit from the protection you get against COVID-19 and the easing of restrictive measures in your community.
This dataset provides the cumulative number of COVID-19 vaccine doses administered in Canada by jurisdiction, vaccine product, and report date. Variables include:
Jurisdiction ID number
Cumulative number of COVID-19 vaccine doses administered
Cumulative number of Pfizer-BioNTech COVID-19 vaccine doses administered
Cumulative number of Moderna COVID-19 vaccine doses administered
Cumulative number of COVID-19 vaccine (unknown product) doses administered
As of date
For variable definitions, see the data dictionary. For details regarding data sources and limitations, see the technical notes section of the Canadian COVID-19 vaccination coverage report (https://health-infobase.canada.ca/covid-19/vaccination-coverage/technical-notes.html).